August 30, 2024 by European Society of Cardiology Credit: Unsplash/CC0 Public DomainVutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session held today, August 30, at ESC Congress 2024. “ATTR is a progressive, fatal disease in...
